INmune Bio Dividends
| INMB Stock | USD 1.54 0.03 1.99% |
As of February 9, 2026, Dividend Paid And Capex Coverage Ratio is expected to decline to -1.8. INmune Bio's past performance could be the main factor of why investors trade INmune Bio stock today. Investors should clearly understand every aspect of the INmune Bio dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest INmune Bio's dividend schedule and payout information. INmune Bio dividends can also provide a clue to the current valuation of INmune Bio.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (1.71) | (1.80) |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in INmune Bio must own a stock before its ex-dividend date to receive its next dividend.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. Market participants price INmune higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive INmune Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth 2.571 | Return On Assets | Return On Equity |
INmune Bio's market price often diverges from its book value, the accounting figure shown on INmune's balance sheet. Smart investors calculate INmune Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since INmune Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.